<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05040334</url>
  </required_header>
  <id_info>
    <org_study_id>Cairo University Obygyn</org_study_id>
    <nct_id>NCT05040334</nct_id>
  </id_info>
  <brief_title>Role of Prophylactic Antibiotics in Preventing Pelvic Infection After Surgical Evacuation</brief_title>
  <official_title>Role of Prophylactic Antibiotics in Preventing Pelvic Infection After Surgical Evacuation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the role of antibiotic prophylaxis in the surgical management of miscarriage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized to receive either prophylactic antibiotic [a single dose of oral&#xD;
      doxycycline (200 mg) and metronidazole (500 mg)] or placebo using identical sealed&#xD;
      envelopes.Included cases are those with early miscarriage (within the first trimester 12 6/7&#xD;
      weeks of gestation) , missed or incomplete miscarriage, undergoing surgical management will&#xD;
      be included in the study.&#xD;
&#xD;
      Technique:&#xD;
&#xD;
      The investigators will prepare 138 identical envelops, half of them filled with a label&#xD;
      group(1) who are the group to receive the antibiotic prophylaxis with all instruction&#xD;
      details, while the other half filled with a label identifying ( group 2) who are the placebo&#xD;
      group. All envelops will be prepared by the investigator and sealed before starting&#xD;
      enrollment. After enrollment, each participant will be allowed to choose one envelop to&#xD;
      determine to which group the patient will be assigned to.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group 1;receiving antibiotic prophylaxis Group 2; Not receiving antibiotics</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>138 identical envelops, half of them filled with a label(Group 1) who are the &quot;Prophylactic antibiotic&quot; group with all instruction details, while the other half are labelled (group 2) who are the &quot;Placebo&quot; group with all instruction details. All envelops will be prepared by the investigator and sealed before starting enrollment. After enrollment, each participant will be allowed to choose one envelop to determine to which group she will be assigned.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change of pelvic infection after surg ical evacuation of miscarriage with use of antibiotic prophylaxis.</measure>
    <time_frame>2 weeks from surgery</time_frame>
    <description>White cell count &gt;12 *10^9 cells / L by CBC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the risk of severe puerperal sepsis following the surgical procedure</measure>
    <time_frame>2 weeks from surgery</time_frame>
    <description>Signs of puerperal sepsis in form of puerperal pyrexia &gt;38 C and/or purulent vaginal discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Antibiotics Causing Adverse Effects in Therapeutic Use</condition>
  <arm_group>
    <arm_group_label>group(1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>69 patients receiving a single dose of oral doxycycline (200 mg) and metronidazole (500 mg)tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group (2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>69 patients receiving placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 1: Antibiotic receiving group</intervention_name>
    <description>Group 1; receiving antibiotic prophylaxis; single dose of oral doxycycline (200 mg) tablet and metronidazole (500 mg) tablet 2 hours before the surgical evacuation Group B ;receiving placebo 2 hours before the surgical evacuation</description>
    <arm_group_label>Group (2)</arm_group_label>
    <arm_group_label>group(1)</arm_group_label>
    <other_name>Group 2 :placebo receiving group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Maternal age :18-35 years&#xD;
&#xD;
          -  Gestational age: up to 12 6/7 weeks of gestation (confirmed by a reliable date for the&#xD;
             last menstrual period or /and 1st trimester ultrasound scan).&#xD;
&#xD;
          -  Singleton miscarriage&#xD;
&#xD;
          -  Type of miscarriage: Incomplete or Missed miscarriage&#xD;
&#xD;
          -  Surgical evacuation will be done within 2 weeks of diagnosis of miscarriage .&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Maternal age: younger than 18 years&#xD;
&#xD;
          -  Induced miscarriage of pregnancy&#xD;
&#xD;
          -  Septic miscarriage&#xD;
&#xD;
          -  Evidence of infection&#xD;
&#xD;
          -  Morbid obesity (BMIâ‰¥40kg/m2)&#xD;
&#xD;
          -  Allergy to prophylactic antibiotics (i.e., doxycycline or metronidazole)&#xD;
&#xD;
          -  Antibiotics use within 7 days before randomization&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marwa Mo Eid, Ass.prof.</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nihal Mo El-Demiry, lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marwa Mo Eid, Ass.professor</last_name>
    <phone>01001225079</phone>
    <email>marwameid2014@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nihal Mo El-Demiry, Lecturer</last_name>
    <phone>01006049052</phone>
    <email>n.eldemiry@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, Kasr Al-Ainy University Hospital, Cairo University.</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marwa Mo Eid, Ass prof</last_name>
      <phone>01001225079</phone>
      <email>marwameid2014@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nihal Mo El-Demiry, Lecturer</last_name>
      <phone>: 01006049052</phone>
      <email>n.eldemiry@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Marwa Mohamed Mahmoud Eid</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pelvic Infection</mesh_term>
    <mesh_term>Pelvic Inflammatory Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

